NCT01373502已完成不适用
International Randomized Comparison Between DES Limus Carbostent and Taxus Drug Eluting Stents in the Treatment of De-novo Coronary Lesions. The NEXT Study.
CID - Carbostent & Implantable Devices15 个研究点 分布在 4 个国家目标入组 323 人开始时间: 2009年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 323
- 试验地点
- 15
- 主要终点
- angiographic efficacy measurement (mm)
研究概览
简要总结
The purpose of this study is to demonstrate non-inferiority in terms of safety and efficacy of DES Limus Carbostent compared to the Taxus Liberté in treating de-novo atherosclerotic lesions in native coronary arteries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Patient is eligible for percutaneous coronary intervention (PCI) and for surgical revascularization (CABG)
- •Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site
- •Patients with clinical evidence of ischemic heart disease and/or a positive functional study(e.g. stress test); documented stable (CCS I-IV) or unstable angina pectoris (Braunwald class I-II B and C) or documented silent ischemia
- •LVEF>30%
- •Requires treatment of a single de novo lesion in a native coronary artery in one or two different major epicardial vessels (LAD, LCX or RCA). The second lesion must fit with inclusion/
排除标准
- •and must be treated with the same study stent as the first lesion
- •Target lesion should be located in a target vessel with a diameter ranging from 3.0 to 3.75 mm
- •Target lesion diameter stenosis > 50% and < 100% by visual estimate, with a TIMI flow of ≥ 1
- •The target lesion must be appropriately covered (margin of 2.5 mm on both sides of the stent) by one study stent (DES Limus Carbostent or Taxus Liberté, according to the randomization arm). Any occurred dissection of the target vessel must be treated with an additional stent (DES Limus Carbostent or Taxus Liberté, according to the randomization arm)
- •Patient that underwent BMS implantation more than 6 months before the enrolment or DES implantation more than 1 year before the enrolment in an other vessel.
- •Exclusion Criteria:
- •Female with childbearing potential or lactating
- •Known sensitivity to sirolimus, paclitaxel, the polymeric matrix, stainless steel or cobalt chromium
- •Acute Q-wave or non Q-wave myocardial infarction within 72 hours, or presents with CK elevation greater than 2 times upper limit normal associated with elevated CK-MB
- •Cardiogenic shock
- •Cerebrovascular accident within the past 6 months
- •Acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl)
- •Contraindication to aspirin or clopidogrel
- •Thrombocytopenia (platelet count less than 100,000/mm³)
- •Active gastrointestinal bleeding within the past 3 months
- •Known bleeding or hypercoagulable disorder
- •Prior anaphylactic reaction to contrast agents or contrast sensitivity that cannot be controlled with pre-medication
- •Currently under immunosuppressant therapy
- •Currently, or has been treated with either Rapamune or paclitaxel within 12 months of the procedure
- •Active infection
- •Co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year;
- •Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study
- •Patient underwent coronary revascularization to any vessel within 30 days
- •Patient underwent target vessel revascularization within 6 months
- •Target vessel has had prior stent placement
- •Presence of two lesions located in the same vascular territory (same major epicardial vessel)
- •Prior coronary brachytherapy
- •There is a planned target lesion treatment with any technique other than the pre-dilatation balloon angioplasty
- •Treatment of more than two lesions is required at the time of enrolment, or is planned within 30 days following enrolment
- •Any planned surgery within 6 months after index procedure
- •Left main disease greater than 50% diameter stenosis
- •Significant (>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off
- •Heavily calcified vessel and/or lesion which cannot be successfully predilated
- •Target lesion is located or supplied by an arterial or venous bypass graft
- •Ostial target lesion or lesion located within 2 mm of a bifurcation
- •Target lesion involves a side branch >2.0 mm in diameter with an ostial disease
- •Target lesion has TIMI 0 flow
- •Target vessel with angiographically visible thrombus or unsuitable for proper stent delivery and deployment.
结局指标
主要结局
angiographic efficacy measurement (mm)
时间窗: 180 days
in-stent Late Lumen Loss (LLL) measurement by angiography
次要结局
- Incidence of clinically indicated TLR (%)(30 days, 180 days, 1, 2, 3, 4, 5 years)
- Incidence of cardiac death (%)(30 days, 180 days, 1, 2 , 3, 4 and 5 years)
- Acute success (Device and Procedural success)(acute)
- Incidence of Myocardial Infarction (%)(30 days, 180 days, 1, 2, 3, 4, 5 years)
- QCA measurements in-stent and in-segment(180 days)
- Stent Thrombosis(acute, 30 days, 180 days, 1 year, > 1 year)
- Incidence of all deaths (%)(30 days, 180 days, 1, 2, 3, 4, 5 years)
- Incidence of all repeat revascularization (%)(30 days, 180 days, 1, 2, 3, 4, 5 years)
- IVUS measurements(180 days)
研究者
研究点 (15)
Loading locations...
相似试验
Unknown
不适用
Bifurcation Stenting Using 2 Link Stent Nobori Versus 3 Link Stent XienceCoronary StenosisNCT01574586Kurashiki Central Hospital240
已完成
不适用
EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.Coronary DiseaseHeart DiseasesCardiovascular DiseasesArterial Occlusive DiseasesVascular DiseasesCoronary Artery DiseaseMyocardial IschemiaArteriosclerosisNCT02057978JW Medical Systems Ltd419
已完成
不适用
Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMSStable AnginaNSTEMIUnstable AnginaNCT01543373CID - Carbostent & Implantable Devices38
已完成
3 期
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.Overactive BladderNCT03575702R-Pharm300
已完成
3 期
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial InfarctionThromboembolismNCT00064428GlaxoSmithKline12,092